More than 40 are designed and operational already. These new hospital developments announced today will become funded mainly through the Private Finance Initiative . It’ll now be for regional health organisations to progress these schemes to the next stages of development. After years of under-investment, the infrastructure of the NHS reaches last being made and modernised fit for the 21st Century. I look forward to seeing further progress on these schemes, and all of the other hospital building projects which are underway, and especially to seeing the benefits they will bring with their local communities.Rita S. Mehta, M.D., William E. Barlow, Ph.D., Kathy S. Albain, M.D., Ted A. Vandenberg, M.D., Shaker R. Dakhil, M.D., Nagendra R. Tirumali, M.D., Danika L. Lew, M.A., Daniel F. Hayes, M.D., Julie R. Gralow, M.D., Robert B. Livingston, M.D., and Gabriel N. Hortobagyi, M.D.1 Selective aromatase inhibitors, such as for example anastrozole, letrozole, and exemestane, lower the estrogen level and so are used as first-line endocrine remedies of HR-positive metastatic disease, due to their superiority over tamoxifen.2 This impact prospects to reduced cross-speak between the estrogen receptor and estrogen-independent growth aspect signaling, thus delaying resistance to hormone therapy.